Earnings Disappointment: Recent discussions on X about Novo Nordisk (NVO) have centered on the company’s disappointing Q2 earnings and a significant cut in its full-year 2025 sales growth forecast. Many are concerned about weakening demand for Wegovy in the U.S. market amid fierce competition in the weight-loss drug sector. The stock’s sharp decline has sparked heated debates over its future prospects.
Strategic Moves: Chatter on X also highlights Novo Nordisk’s aggressive push into acquisitions, with a notable bid for a competitor in the weight-loss space. Some see potential in rumored partnerships and upcoming earnings on November 5 as catalysts for recovery. However, concerns persist about pricing pressures and regulatory risks in the obesity therapeutics market.
Note: This discussion summary was generated from an AI condensation of post data.
Novo Nordisk Congressional Stock Trading
Members of Congress have traded $NVO stock 12 times in the past 6 months. Of those trades, 9 have been purchases and 3 have been sales.
Here’s a breakdown of recent trading of $NVO stock by members of Congress over the last 6 months:
- REPRESENTATIVE MARJORIE TAYLOR GREENE has traded it 3 times. They made 3 purchases worth up to $80,000 on 10/15, 08/28, 08/19 and 0 sales.
- REPRESENTATIVE LISA C. MCCLAIN has traded it 4 times. They made 2 purchases worth up to $30,000 on 09/11, 06/09 and 2 sales worth up to $30,000 on 08/04, 07/10.
- REPRESENTATIVE SCOTT FRANKLIN has traded it 4 times. They made 4 purchases worth up to $95,000 on 08/04 and 0 sales.
- REPRESENTATIVE LAUREL M. LEE sold up to $15,000 on 05/08.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
Novo Nordisk Hedge Fund Activity
We have seen 651 institutional investors add shares of Novo Nordisk stock to their portfolio, and 804 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- JENNISON ASSOCIATES LLC removed 17,659,339 shares (-93.5%) from their portfolio in Q3 2025, for an estimated $979,916,721
- KINGSTONE CAPITAL PARTNERS TEXAS, LLC removed 10,005,216 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $555,189,435
- AMUNDI removed 4,938,507 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $340,855,753
- FMR LLC added 4,308,228 shares (+44.7%) to their portfolio in Q2 2025, for an estimated $297,353,896
- TWO SIGMA ADVISERS, LP removed 3,465,100 shares (-71.3%) from their portfolio in Q2 2025, for an estimated $239,161,202
- NUVEEN, LLC removed 3,236,504 shares (-60.7%) from their portfolio in Q2 2025, for an estimated $223,383,506
- D. E. SHAW & CO., INC. removed 2,582,572 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $178,249,119
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Novo Nordisk Analyst Ratings
Wall Street analysts have issued reports on $NVO in the last several months. We have seen 3 firms issue buy ratings on the stock, and 2 firms issue sell ratings.
Here are some recent analyst ratings:
- Jefferies issued a "Underperform" rating on 10/27/2025
- HSBC issued a "Buy" rating on 10/02/2025
- Morgan Stanley issued a "Underweight" rating on 09/29/2025
- Berenberg issued a "Buy" rating on 09/17/2025
- TD Cowen issued a "Buy" rating on 08/19/2025
To track analyst ratings and price targets for Novo Nordisk, check out Quiver Quantitative's $NVO forecast page.
Novo Nordisk Price Targets
Multiple analysts have issued price targets for $NVO recently. We have seen 4 analysts offer price targets for $NVO in the last 6 months, with a median target of $62.5.
Here are some recent targets:
- Evan David Seigerman from BMO Capital set a target price of $55.0 on 10/14/2025
- Rajesh Kumar from HSBC set a target price of $70.0 on 10/02/2025
- Thibault Boutherin from Morgan Stanley set a target price of $47.0 on 09/29/2025
- Michael Nedelcovych from TD Cowen set a target price of $70.0 on 08/19/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
